A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer

A. Tognoni; F. Pensa; F. Vaira; A. Vigani; L. Bancalari; L. Fiasella; R. Maggiani; P. Canessa; P. Pronzato

A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer

A. Tognoni, F. Pensa, F. Vaira, A. Vigani, L. Bancalari, L. Fiasella, R. Maggiani, P. Canessa, P. Pronzato

A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)

Research output: Contribution to journal › Article › peer-review

Abstract

We have carried out a pilot study on 25 non-small cell lung cancer patients, administering the combination of gemcitabine at the dose of 1000 mg/m ² on days 1 and 8, ifosfamide 1500 mg/m ² on days 1 and 2 (plus mesna as uroprotector) and cisplatin 40 mg/m ² on days 1 and 2, every 21 days. Granulocyte Colony Stimulating Factor was employed in all cases from day 10 to day 18 at the dose of 300 μg daily. An objective response was observed in 11 cases (44%). The regimen was active, but toxicity was remarkable with some cases of severe myelosuppression and mucositis.

Original language	English
Pages (from-to)	202-205
Number of pages	4
Journal	Journal of Chemotherapy
Volume	13
Issue number	2
Publication status	Published - 2001

Keywords

Cisplatin
Gemcitabine
Ifosfamide
Non-small-cell lung cancer
Toxicity in cancer therapy

ASJC Scopus subject areas

Pharmacology (medical)
Microbiology (medical)

Cite this

@article{e7559a113d9b44319b22ceb70952ef1d,

title = "A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer",

abstract = "We have carried out a pilot study on 25 non-small cell lung cancer patients, administering the combination of gemcitabine at the dose of 1000 mg/m 2 on days 1 and 8, ifosfamide 1500 mg/m 2 on days 1 and 2 (plus mesna as uroprotector) and cisplatin 40 mg/m 2 on days 1 and 2, every 21 days. Granulocyte Colony Stimulating Factor was employed in all cases from day 10 to day 18 at the dose of 300 μg daily. An objective response was observed in 11 cases (44%). The regimen was active, but toxicity was remarkable with some cases of severe myelosuppression and mucositis.",

keywords = "Cisplatin, Gemcitabine, Ifosfamide, Non-small-cell lung cancer, Toxicity in cancer therapy",

author = "A. Tognoni and F. Pensa and F. Vaira and A. Vigani and L. Bancalari and L. Fiasella and R. Maggiani and P. Canessa and P. Pronzato",

year = "2001",

language = "English",

volume = "13",

pages = "202--205",

journal = "Journal of Chemotherapy",

issn = "1120-009X",

publisher = "Maney Publishing",

number = "2",

}

TY - JOUR

T1 - A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer

AU - Tognoni, A.

AU - Pensa, F.

AU - Vaira, F.

AU - Vigani, A.

AU - Bancalari, L.

AU - Fiasella, L.

AU - Maggiani, R.

AU - Canessa, P.

AU - Pronzato, P.

PY - 2001

Y1 - 2001

N2 - We have carried out a pilot study on 25 non-small cell lung cancer patients, administering the combination of gemcitabine at the dose of 1000 mg/m 2 on days 1 and 8, ifosfamide 1500 mg/m 2 on days 1 and 2 (plus mesna as uroprotector) and cisplatin 40 mg/m 2 on days 1 and 2, every 21 days. Granulocyte Colony Stimulating Factor was employed in all cases from day 10 to day 18 at the dose of 300 μg daily. An objective response was observed in 11 cases (44%). The regimen was active, but toxicity was remarkable with some cases of severe myelosuppression and mucositis.

AB - We have carried out a pilot study on 25 non-small cell lung cancer patients, administering the combination of gemcitabine at the dose of 1000 mg/m 2 on days 1 and 8, ifosfamide 1500 mg/m 2 on days 1 and 2 (plus mesna as uroprotector) and cisplatin 40 mg/m 2 on days 1 and 2, every 21 days. Granulocyte Colony Stimulating Factor was employed in all cases from day 10 to day 18 at the dose of 300 μg daily. An objective response was observed in 11 cases (44%). The regimen was active, but toxicity was remarkable with some cases of severe myelosuppression and mucositis.

KW - Cisplatin

KW - Gemcitabine

KW - Ifosfamide

KW - Non-small-cell lung cancer

KW - Toxicity in cancer therapy

UR - http://www.scopus.com/inward/record.url?scp=0035057693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035057693&partnerID=8YFLogxK

M3 - Article

C2 - 11330369

AN - SCOPUS:0035057693

VL - 13

SP - 202

EP - 205

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 2

ER -

A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this